Riociguat: PATENT-1 Study

Stimulators of soluble guanylate cyclase (sCG) are novel pharmacological agents that directly stimulate sGC. Ongoing research on sGC stimulators led to the development of the more potent and more specific sGC stimulator, riociguat. Recently, the US Food and Drug Administration has approved riociguat...

Descripción completa

Detalles Bibliográficos
Autor principal: Said, Karim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bloomsbury Qatar Foundation Journals 2014
Materias:
Lessons from the Trials
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4220430/
https://www.ncbi.nlm.nih.gov/pubmed/25405174
http://dx.doi.org/10.5339/gcsp.2014.21
Descripción
Sumario:Stimulators of soluble guanylate cyclase (sCG) are novel pharmacological agents that directly stimulate sGC. Ongoing research on sGC stimulators led to the development of the more potent and more specific sGC stimulator, riociguat. Recently, the US Food and Drug Administration has approved riociguat to treat pulmonary arterial hypertension in adults. Support for the approval of riociguat comes from the recently published PATENT-1 (Pulmonary Arterial Hypertension Soluble Guanylate Cyclase–Stimulator Trial 1) study.

Ejemplares similares